A new frontier in cancer therapy: Mo2C MXene nanoreactors activated by deep-tissue light
A study published in *Molecular Pharmaceutics* details the development of a novel cascade nanoreactor for cancer treatment, built upon a foundation of Mo2C MXene. This platform is engineered for activation by near-infrared light in the second biological window (NIR-II), which allows for deeper tissue penetration compared to traditional wavelengths. The system is designed for multimodal therapy, potentially combining photothermal effects with targeted drug delivery or other therapeutic mechanisms to attack tumors more effectively and with greater precision.
Why it might matter to you: While focused on oncology, the core technology of a light-activated, deep-tissue therapeutic platform has significant translational potential for pulmonary medicine. For specialists in lung cancer, this represents an emerging avenue for targeted, minimally invasive treatment of thoracic tumors. Furthermore, the principles of advanced drug delivery and localized activation could inform future inhaled therapeutics for other complex respiratory diseases, aiming to maximize efficacy at the site of airway inflammation or infection while minimizing systemic side effects.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
